NLS Pharmaceutics Announces Technology Patent Grant Covering Mazindol for Treatment of Attention Deficit Hyperactivity Disorder and Rare Sleep Disorders in Hong Kong
Stock Information for NLS Pharmaceutics Ltd.
Loading
Please wait while we load your information from QuoteMedia.